226 related articles for article (PubMed ID: 36602564)
1. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
Roskoski R
Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
[TBL] [Abstract][Full Text] [Related]
3. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
[TBL] [Abstract][Full Text] [Related]
4. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
5. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
7. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
8. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
[TBL] [Abstract][Full Text] [Related]
9. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
11. Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.
Malyukova A; Ujvari D; Yektaei-Karin E; Zovko A; Madapura HS; Keszei M; Nagy N; Lotfi K; Björn N; Wallvik J; Tamai M; Nguyen TTT; Akahane K; Inukai T; Stenke L; Salamon D
Cell Death Dis; 2021 Sep; 12(10):875. PubMed ID: 34564697
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
16. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
Front Immunol; 2018; 9():2433. PubMed ID: 30405627
[TBL] [Abstract][Full Text] [Related]
17. Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.
Žáčková M; Macháčková-Lopotová T; Ondráčková Z; Kuželová K; Klamová H; Moravcová J
Blood Cells Mol Dis; 2016 May; 58():67-75. PubMed ID: 27067491
[TBL] [Abstract][Full Text] [Related]
18. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
19. Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia.
Ozel B; Kipcak S; Biray Avci C; Sabour Takanlou M; Sabour Takanlou L; Tezcanli Kaymaz B; Karatekin I; Gunduz C; Selvi Gunel N
Med Oncol; 2022 Jun; 39(9):126. PubMed ID: 35716222
[TBL] [Abstract][Full Text] [Related]
20. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
